The BioMed X Institute
A new research team at XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
RIDGEFIELD, CT / ACCESSWIRE / May 16, 2024 / XSeed Labs - a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut. This research team's main objective is to develop complex, physiologically relevant disease models that deepen our understanding of dysfunctional wound healing and fibrosis. The end goal is to study fibrosis, drug delivery strategies, and drug safety in parallel, in an effort to bridge the gap between research and development to improve patient outcomes accurately and efficiently.
The new research team is led by Dr. Lorenzo Talà, Group Leader at XSeed Labs. "Due to insufficient understanding of the mechanisms driving their pathology, therapies to treat fibrotic diseases are limited. The aim of our research group is to develop physiologically relevant in vitro and in silico fibrosis models. By combining both approaches, we will interrogate disease mechanisms, identify drug delivery pathways, and assess drug safety in order to facilitate drug development toward resolving fibrotic tissues."
Christian Tidona, Founder and Managing Director of the BioMed X Institute: "We are pleased that we could successfully translate the innovation model we established in Heidelberg and New Haven to work inside a major pharma research and development campus. We have a long history of successful collaboration with Boehringer Ingelheim at our Heidelberg institute, and we are proud to extend this collaboration to their U.S. headquarters in Ridgefield, Connecticut."
"We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases," said Carine Boustany, PhD, U.S. Research Site Head and Global Head of Immunology and Respiratory Diseases Research, Boehringer Ingelheim. "In parallel, we will harness these innovative disease model systems to assess the safety of novel anti-fibrotic concepts, and identify better ways to deliver our molecules," said Xiaorong He, PhD, U.S. Development Site Head and Global Head of Development Sciences, Boehringer Ingelheim.
"We are excited to start our first XSeed Labs team at Boehringer Ingelheim in Ridgefield. It is the beginning of a unique innovation model that promotes scientific exchange between major players in biomedical research," says Mark Johnston, CEO of BioMed X USA.
About BioMed X and XSeed Labs
BioMed X is an independent research institute with sites in Heidelberg, Germany, New Haven, Connecticut, XSeed Labs in Ridgefield, Connecticut, and a worldwide network of partner locations. Together with our partners, we identify big biomedical research challenges and provide creative solutions by combining global crowdsourcing with local incubation of the world's brightest early-career research talents. Each of the highly diverse research teams at BioMed X has access to state-of-the-art research infrastructure and is continuously guided by experienced mentors from academia and industry. At BioMed X, we combine the best of two worlds -- academia and industry -- and enable breakthrough innovation by making biomedical research more efficient, more agile, and more fun.
BioMed X started working with Boehringer Ingelheim in 2015 with a series of joint research projects hosted by the BioMed X Institute in Heidelberg, Germany. The new collaboration model - called XSeed Labs - entails an open innovation incubator embedded in the Boehringer Ingelheim Ridgefield campus in Connecticut, USA.
Contact Information
Flavia-Bianca Cristian
Recruiting & Communications Manager
fbc@bio.mx
+49 6221 426 11 706
Swathi Lingam
Scientific Communication & Editorial Associate
lingam@bio.mx
+49 6221 426 11 27
Related Images
SOURCE: BioMed X Institute & XSeed Labs
To view this piece of content from stats.nwe.io, please give your consent at the top of this page.View the original press release on newswire.com.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Expands Blue Carbon Leadership with New Restoration Project in Guinea7.11.2025 14:00:00 CET | Press release
New initiative in the Konkouré Delta builds on Senegal's success, advancing coastal restoration, biodiversity, and community resilience across West Africa. CONAKRY, GN / ACCESS Newswire / November 7, 2025 / Building on the success of its 7,000-hectare mangrove reforestation project in Senegal-which has already generated an estimated 2.8 million tonnes of CO₂ reductions and measurable community benefits-Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company") is expanding its blue carbon leadership into the Konkouré Delta of Guinea, as blue carbon emerges as a critical frontier for climate investment and coastal resilience. Developed through ALLCOT - A Karbon-X Company, the project development and advisory arm of Karbon-X, the initiative will replicate and scale the proven model from Senegal, enhancing biodiversity, shoreline protection, and sustainable livelihoods across West Africa. Mangroves are more than trees; they are natural shields protecting coastlines, nurseries for marine li
Innodata Reports Third Quarter 2025 Results6.11.2025 22:30:00 CET | Press release
Revenue up 20% Year-Over-Year Reiterates Prior Guidance of 45% or More YoY Growth in 2025 Anticipates Transformative Growth in 2026 Based on New Wins and Strong Momentum NEW YORK CITY, NY / ACCESS Newswire / November 6, 2025 / INNODATA INC. (Nasdaq:INOD) today reported results for the third quarter ended September 30, 2025. Revenue of $62.6 million for the three months ended September 30, 2025, representing 20% year-over-year organic revenue growth. Revenue of $179.3 million for the nine months ended September 30, 2025, representing 61% year-over-year organic revenue growth. Adjusted EBITDA of $16.2 million for the three months ended September 30, 2025, an increase of $2.3 million, or 17%, from $13.9 million in the same period last year.* Adjusted EBITDA of $42.2 million for the nine months ended September 30, 2025, an increase of $21.8 million, or 106%, from $20.4 million in the same period last year.* Net income of $8.3 million, or $0.26 per basic share and $0.24 per diluted share, f
Innodata Announces New Leadership Appointments to Support Next Phase of Growth6.11.2025 22:05:00 CET | Press release
Rahul Singhal Appointed President and Chief Revenue Officer Daniel H. (Don) Callahan and General (Retired) Richard D. Clarke Appointed to Board Jack Abuhoff Appointed Chairman Stewart Massey Appointed Lead Independent Director NEW YORK, NY / ACCESS Newswire / November 6, 2025 / Innodata Inc. (Nasdaq:INOD), a global data-engineering company, today announced executive management and Board appointments to support the Company's rapid growth and continued global expansion in generative AI solutions and platforms. Rahul Singhal Appointed President and Chief Revenue Officer Rahul Singhal, formerly Innodata's Chief Product Officer and Chief Revenue Officer, has been promoted to President and Chief Revenue Officer. In his expanded role, Singhal will define the Company's overall product strategy, product roadmap, and go-to-market execution across the Company's AI, data engineering, and digital transformation businesses. "Rahul has been instrumental in shaping our strategy for sustained growth an
Innodata Launches Federal Business Unit to Support Accelerating AI Innovation Across U.S. Government6.11.2025 22:05:00 CET | Press release
New Unit Positions Company to Serve Defense, Intelligence, and Civilian Agencies with Proven AI Data Engineering, Generative AI, and Agentic AI Solutions NEW YORK, NY / ACCESS Newswire / November 6, 2025 / INNODATA INC. (Nasdaq:INOD) today announced the launch of Innodata Federal, a dedicated government-focused business unit designed to deliver mission-critical AI solutions to U.S. defense, intelligence, and civilian agencies. The new unit emerges as federal acquisition authorities are rapidly evolving to prioritize commercial innovation through Other Transaction Authorities (OTAs), Commercial Solutions Openings (CSOs), and streamlined procurement pathways that favor speed, flexibility, and proven commercial capabilities. The launch, announced alongside Innodata's earnings release and a press release announcing that General (Retired) Richard D. Clarke, a retired four-star Army general and former Commander of U.S. Special Operations Command, has joined the Innodata board, positions the
The Michelin Guide Expands Its Global Footprint with the Arrival in Aotearoa New Zealand5.11.2025 20:00:00 CET | Press release
AUCKLAND, NZ / ACCESS Newswire / November 5, 2025 / Michelin is pleased to announce the arrival of the MICHELIN Guide in Aotearoa New Zealand, marking its first-ever expansion into Oceania. The inaugural edition will cover four vibrant culinary destinations: Auckland, Wellington, Christchurch, and Queenstown. Set to be unveiled in the middle of 2026, the restaurant selection process is already under way, as MICHELIN Guide Inspectors are currently on the ground, dining anonymously to identify the very best restaurants that showcase the unique character of Auckland, Wellington, Christchurch, and Queenstown culinary scenes. Gwendal Poullennec, International Director of the MICHELIN Guide states: "We are thrilled to bring the MICHELIN Guide to Aotearoa New Zealand for the very first time. The country offers a rich and diverse culinary landscape, shaped by its indigenous Māori heritage, Pacific influences, and a new generation of chefs who champion local produce with creativity and passion.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom